Clinical Data ASCO26: In vivo oncology approaches continue to show promise Pharmaceutical TechnologyLilly's $7bn acquisition of Kelonia seems to be bearing fruit, with other in vivo approaches showing promise at ASCO 2026.OncologyRead full story pharminent June 2, 2026 (Last updated: June 3, 2026) Pharmaceutical Technology Lilly’s $7bn acquisition of Kelonia seems to be bearing fruit, with other in vivo approaches showing promise at ASCO 2026. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to comeNext: ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma Related Stories Clinical Data Boehringer advances duo for aggressive cancers into phase 3 pharminent June 22, 2026 Clinical Data Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls short pharminent June 17, 2026 Clinical Data EHA26: BMS touts positive multiple myeloma data for two pipeline candidates pharminent June 17, 2026
